[HTML][HTML] Realizing the promise of dolutegravir in effectively treating children and adolescents living with HIV in real-world settings in 6 countries in Eastern and …

JM Bacha, S Dlamini, F Anabwani… - The Pediatric …, 2023 - journals.lww.com
Background: Despite encouraging results from clinical trials and in high-income countries,
large-scale data on the effectiveness and safety of dolutegravir (DTG) in children and …

Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed …

W Sribenjalux, T Nuntawit, A Meesing… - … journal of STD & …, 2023 - journals.sagepub.com
Background A ritonavir-boosted protease inhibitor (PI)-based antiretroviral therapy (ART)
regimen can cause abnormal lipid levels and increased incidence of cardiovascular …

CD4/CD8 Ratio Outcome According to the Class of the Third Active Drug in Antiretroviral Therapy Regimens: Results From the Quebec Human Immunodeficiency …

MN Sangaré, JG Baril, A De Pokomandy… - Clinical Infectious …, 2023 - academic.oup.com
Background The impact of different therapeutic classes of drugs in antiretroviral therapy
(ART) regimens on the CD4/CD8 ratio is not well documented in people treated for HIV. The …

EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN: Dolutegravir in HIV

F Batool, S Manzoor, AK Dhiloo, HM Ismail… - Pakistan Armed Forces …, 2021 - pafmj.org
Objective: To study the tolerability and efficacy of dolutegravir in naïve and experienced
patients, their management and outcome. Study Design: Cross sectional study. Place and …

Antiretroviral therapy use, and self-reported adherence and viral suppression among women living with HIV in Canada

M Mokaddam - 2024 - escholarship.mcgill.ca
Background: In Canada, an estimated 62,790 people are living with HIV, 24.6% of which are
female. Antiretroviral therapy (ART) suppresses viral replication to undetectable levels …

Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settings

T Marukutira, BR Wood - AIDS, 2021 - journals.lww.com
The WHO now recommends dolutegravir (DTG)-based regimens as the preferred option for
first-line and second-line antiretroviral therapy (ART) for all persons with HIV [1, 2]. For initial …

Cohorte de patients vivant avec le VIH et ayant de la résistance prouvée ou présumée: analyse des changements de traitement pour une trithérapie contenant deux …

MN SANGARÉ - 2021 - papyrus.bib.umontreal.ca
Des progrès importants ont été réalisés dans la thérapie des personnes vivant avec le VIH
(PVVIH) avec le développement d'antirétroviraux (ARV) de plus en plus efficaces, sûrs avec …